

Content

Figure S1. Flow chart for the inclusion of SARS-CoV-2 PCR-positive subjects (tested between 1 st October 2020 and 1 st April 2021) aged 18-65 years from defined regions in southern Germany.	2
Figure S2. Prevalence of symptoms before (pre), during, and 6-12 months after (current) after the SARS-CoV-2 infection, including prevalence ratio (current divided by pre) and prevalence difference (current minus pre) with 95 % confidence intervals according to age categories and sex. N represents the number of respondents in the respective age strata.	3
Figure S3. Frequency of symptoms 6-12 months after acute infection, given the symptom was not present before the infection, stratified according to sex with grade of impairment (top panel) and medical treatment (bottom panel).	13
Figure S4. Co-occurrence network of symptom clusters 6-12 months after SARS-CoV-2 infection (with prevalence in %), given the symptoms were not present before the infection, along with contributing individual symptoms of grade moderate to strong	14
Table S1. Fatigue assessment scale (FAS) scores by new (not present before the infection) self-reported fatigue (as most prevalent symptom cluster)	15
Figure S5. Pairwise agreement (Cohen's kappa) between symptom clusters (left panel) and conditional probability (right panel) of experiencing symptoms of a specific cluster (columns) given another specific symptom cluster (rows). The overall prevalence of a specific symptom cluster is included in diagonal cells.	15
Table S2. Mutually adjusted prevalence ratios with 95% confidence intervals for new symptom clusters	16
Table S3. Mutually adjusted prevalence ratios with 95% confidence intervals for new symptom clusters with grade of impairment moderate to strong.....	18
Figure S6. Attributable percentage loss of general health (left panel) and working capacity (right panel), stratified by age categories and sex.	20
Figure S7. Pairwise Pearson's correlation coefficient between measures of recovered general health, working capacity, physical and mental health score (SF-12), and fatigue assessment.	21
Table S8. Participation according to age and sex.	21




Figure S1. Flow chart for the inclusion of SARS-CoV-2 PCR-positive subjects (tested between 1st October 2020 and 1st April 2021) aged 18–65 years from defined regions in southern Germany.




Figure S2. Prevalence of symptoms before (pre), during, and 6-12 months after (current) after the SARS-CoV-2 infection, including prevalence ratio (current divided by pre) and prevalence difference (current minus pre) with 95 % confidence intervals according to age categories and sex. N represents the number of respondents in the respective age strata.




Figure S2. Prevalence of symptoms before (pre), during, and 6-12 months after (current) after the SARS-CoV-2 infection, including prevalence ratio (current divided by pre) and prevalence difference (current minus pre) with 95 % confidence intervals according to age categories and sex. N represents the number of respondents in the respective age strata. (...continued)




Figure S2. Prevalence of symptoms before (pre), during, and 6-12 months after (current) after the SARS-CoV-2 infection, including prevalence ratio (current divided by pre) and prevalence difference (current minus pre) with 95 % confidence intervals according to age categories and sex. N represents the number of respondents in the respective age strata. (...continued)




Figure S2. Prevalence of symptoms before (pre), during, and 6-12 months after (current) after the SARS-CoV-2 infection, including prevalence ratio (current divided by pre) and prevalence difference (current minus pre) with 95 % confidence intervals according to age categories and sex. N represents the number of respondents in the respective age strata. (...continued)




Figure S2. Prevalence of symptoms before (pre), during, and 6-12 months after (current) after the SARS-CoV-2 infection, including prevalence ratio (current divided by pre) and prevalence difference (current minus pre) with 95 % confidence intervals according to age categories and sex. N represents the number of respondents in the respective age strata. (...continued)




Figure S2. Prevalence of symptoms before (pre), during, and 6-12 months after (current) after the SARS-CoV-2 infection, including prevalence ratio (current divided by pre) and prevalence difference (current minus pre) with 95 % confidence intervals according to age categories and sex. N represents the number of respondents in the respective age strata. (...continued)




Figure S2. Prevalence of symptoms before (pre), during, and 6-12 months after (current) after the SARS-CoV-2 infection, including prevalence ratio (current divided by pre) and prevalence difference (current minus pre) with 95 % confidence intervals according to age categories and sex. (...continued)




Figure S2. Prevalence of symptoms before (pre), during, and 6-12 months after (current) after the SARS-CoV-2 infection, including prevalence ratio (current divided by pre) and prevalence difference (current minus pre) with 95 % confidence intervals according to age categories and sex. N represents the number of respondents in the respective age strata. (...continued)




Figure S2. Prevalence of symptoms before (pre), during, and 6-12 months after (current) after the SARS-CoV-2 infection, including prevalence ratio (current divided by pre) and prevalence difference (current minus pre) with 95 % confidence intervals according to age categories and sex. N represents the number of respondents in the respective age strata. (...continued)




Figure S2. Prevalence of symptoms before (pre), during, and 6-12 months after (current) after the SARS-CoV-2 infection, including prevalence ratio (current divided by pre) and prevalence difference (current minus pre) with 95 % confidence intervals according to age categories and sex. N represents the number of respondents in the respective age strata. (...continued)




Figure S3. Frequency of symptoms 6-12 months after acute infection, given the symptom was not present before the infection, stratified according to sex with grade of impairment (top panel) and medical treatment (bottom panel).




Figure S4. Co-occurrence network of symptom clusters 6-12 months after SARS-CoV-2 infection (with prevalence in %), given the symptoms were not present before the infection, along with contributing individual symptoms of grade moderate to strong.

Table S1. Fatigue assessment scale (FAS) scores by new (not present before the infection) self-reported fatigue (as most prevalent symptom cluster)

Fatigue assessment scale (FAS)	All N=10 956	No fatigue N=6879	Fatigue with grade of impairment		
			none/light N=1554	moderate N=1443	strong N=1080
Total score, mean (sd)	21·7 (8·9)	17·7 (6·5)	23·5 (6·4)	28·7 (6·9)	35·5 (7·3)
Physical sub-scale, mean (sd)	11·9 (4·9)	9·7 (3·7)	13·0 (3·4)	15·9 (3·5)	19·3 (3·3)
Mental sub-scale, mean (sd)	9·8 (4·5)	8·0 (3·3)	10·6 (3·6)	12·7 (4·1)	16·1 (4·7)
Proportion with FAS score >22, N (%)	4570 (41·7)	1409 (20·5)	910 (58·6)	1208 (83·7)	1043 (96·6)
Proportion with FAS score >34, N (%)	1228 (11·2)	211 (3·1)	95 (6·1)	301 (20·9)	621 (57·5)




Figure S5. Pairwise agreement (Cohen's kappa) between symptom clusters (left panel) and conditional probability (right panel) of experiencing symptoms of a specific cluster (columns) given another specific symptom cluster (rows). The overall prevalence of a specific symptom cluster is included in diagonal cells.

Table S2. Mutually adjusted prevalence ratios with 95% confidence intervals for new symptom clusters

	Any	Fatigue	Neurocognitive impairment	Chest symptoms	Smell or taste disorder	Anxiety/depression	Headache/dizziness
Age, per 10 years	1·00 (0·99-1·01)	1·04 (1·01-1·06)	1·04 (1·01-1·06)	0·98 (0·96-1·00)	0·94 (0·92-0·97)	1·05 (1·01-1·08)	0·99 (0·96-1·02)
Sex							
Male (ref.)							
Female	1·20 (1·16-1·24)	1·27 (1·21-1·34)	1·32 (1·24-1·40)	1·27 (1·19-1·35)	1·25 (1·16-1·35)	1·32 (1·22-1·44)	1·32 (1·21-1·44)
University entrance qualification							
Yes (ref.)							
No	1·02 (0·99-1·06)	1·05 (1·00-1·11)	1·02 (0·96-1·08)	1·08 (1·02-1·15)	1·03 (0·96-1·11)	1·03 (0·96-1·12)	1·11 (1·03-1·21)
Smoking status, N (%)							
Never (ref.)							
Former	1·07 (1·04-1·11)	1·10 (1·04-1·17)	1·18 (1·11-1·25)	1·14 (1·07-1·22)	1·05 (0·97-1·14)	1·11 (1·02-1·21)	1·14 (1·04-1·24)
Current	1·06 (1·01-1·11)	1·17 (1·08-1·26)	1·11 (1·01-1·22)	1·17 (1·06-1·28)	1·03 (0·92-1·16)	1·22 (1·08-1·38)	1·24 (1·09-1·40)
BMI, per 5 kg/m ²	1·02 (1·01-1·03)	1·05 (1·03-1·07)	1·04 (1·02-1·07)	1·10 (1·07-1·13)	1·00 (0·96-1·03)	1·02 (0·99-1·06)	1·04 (1·01-1·08)
Time since positive PCR, per month	1·00 (0·99-1·01)	1·00 (0·98-1·01)	1·01 (0·99-1·03)	1·00 (0·98-1·02)	1·04 (1·02-1·07)	1·00 (0·98-1·03)	0·99 (0·97-1·02)
Treatment of acute SARS-CoV-2 infection							
No medical care (ref.)							
Outpatient care	1·36 (1·33-1·40)	1·79 (1·70-1·88)	1·87 (1·76-1·98)	1·83 (1·72-1·95)	1·33 (1·22-1·44)	2·05 (1·89-2·22)	1·94 (1·78-2·11)
Inpatient care	1·41 (1·34-1·48)	1·89 (1·73-2·07)	1·93 (1·74-2·14)	1·96 (1·75-2·18)	1·23 (1·02-1·48)	2·17 (1·87-2·52)	2·10 (1·79-2·46)
Pre-existing conditions							
Musculoskeletal disorders	1·12 (1·09-1·16)	1·17 (1·11-1·23)	1·20 (1·13-1·27)	1·24 (1·16-1·32)	1·22 (1·13-1·32)	1·24 (1·14-1·34)	1·29 (1·18-1·40)
Cardiovascular disorders	1·07 (1·03-1·11)	1·11 (1·04-1·18)	1·04 (0·97-1·12)	1·14 (1·06-1·23)	1·04 (0·94-1·15)	1·05 (0·95-1·16)	1·02 (0·92-1·13)
Neurological or sensory disorders	1·04 (1·01-1·08)	1·05 (0·99-1·12)	1·12 (1·05-1·20)	1·13 (1·05-1·21)	1·06 (0·97-1·16)	1·05 (0·95-1·15)	0·99 (0·89-1·09)
Metabolic disorders	1·05 (1·02-1·09)	1·12 (1·05-1·19)	1·12 (1·05-1·20)	1·09 (1·02-1·17)	1·07 (0·98-1·18)	1·06 (0·96-1·16)	1·13 (1·03-1·25)
Mental disorders	1·10 (1·06-1·14)	1·16 (1·09-1·24)	1·19 (1·11-1·28)	1·11 (1·02-1·19)	1·08 (0·98-1·19)	0·91 (0·81-1·01)	1·17 (1·05-1·30)
Respiratory diseases	1·06 (1·02-1·10)	1·15 (1·08-1·22)	1·12 (1·04-1·20)	1·09 (1·01-1·18)	0·91 (0·82-1·01)	1·04 (0·94-1·15)	1·10 (0·99-1·22)
Dermatological diseases	1·03 (0·99-1·08)	1·01 (0·94-1·08)	1·04 (0·96-1·13)	1·03 (0·95-1·12)	1·07 (0·96-1·19)	1·10 (0·98-1·22)	0·92 (0·82-1·04)
Cancer	1·02 (0·95-1·09)	0·97 (0·86-1·10)	1·03 (0·91-1·18)	0·99 (0·85-1·14)	1·08 (0·91-1·30)	0·87 (0·71-1·07)	0·95 (0·77-1·17)

Table S2. Mutually adjusted prevalence ratios with 95% confidence intervals for new symptom clusters (...continued)

	Musculoskeletal pain	Upper respiratory symptoms	Rash/paresthesia	Hair loss	Abdominal symptoms	Nausea/vomiting	Chills/fever
Age, per 10 years	1·20 (1·16-1·25)	1·12 (1·07-1·16)	1·10 (1·04-1·15)	0·97 (0·92-1·03)	1·02 (0·95-1·09)	1·01 (0·92-1·10)	1·07 (0·95-1·20)
Sex							
Male (ref.)							
Female	1·36 (1·24-1·49)	1·14 (1·03-1·26)	1·36 (1·20-1·54)	4·77 (3·86-5·90)	1·35 (1·13-1·61)	2·02 (1·57-2·60)	1·51 (1·13-2·01)
University entrance qualification							
Yes							
No	1·13 (1·03-1·24)	1·17 (1·06-1·30)	0·88 (0·78-0·99)	1·12 (0·97-1·30)	1·17 (0·99-1·39)	1·27 (1·02-1·58)	1·14 (0·86-1·51)
Smoking status, N (%)							
Never (ref.)							
Former	1·07 (0·97-1·18)	0·93 (0·83-1·04)	1·20 (1·05-1·37)	0·99 (0·84-1·17)	1·03 (0·86-1·24)	1·37 (1·09-1·73)	1·25 (0·93-1·66)
Current	1·37 (1·20-1·56)	1·28 (1·11-1·49)	1·41 (1·17-1·70)	1·02 (0·81-1·30)	1·08 (0·83-1·42)	1·60 (1·18-2·17)	1·72 (1·17-2·51)
BMI, per 5 kg/m ²	1·08 (1·04-1·12)	1·09 (1·04-1·14)	1·08 (1·02-1·14)	1·07 (1·01-1·13)	0·98 (0·90-1·07)	0·94 (0·84-1·05)	1·01 (0·89-1·14)
Time since positive PCR, per month	0·99 (0·97-1·02)	0·98 (0·95-1·01)	1·01 (0·98-1·05)	0·88 (0·84-0·92)	0·98 (0·93-1·03)	0·96 (0·90-1·02)	0·96 (0·88-1·03)
Treatment of acute SARS-CoV-2 infection							
No medical care (ref.)							
Outpatient care	2·16 (1·97-2·37)	2·07 (1·86-2·29)	2·08 (1·82-2·37)	2·24 (1·93-2·61)	2·41 (2·02-2·88)	2·33 (1·85-2·92)	3·08 (2·33-4·06)
Inpatient care	2·17 (1·83-2·56)	1·79 (1·46-2·20)	3·03 (2·45-3·74)	4·06 (3·22-5·11)	2·74 (1·98-3·78)	2·70 (1·76-4·14)	3·42 (2·10-5·57)
Pre-existing conditions							
Musculoskeletal disorders	1·21 (1·10-1·32)	1·29 (1·16-1·43)	1·13 (0·99-1·29)	1·07 (0·91-1·25)	1·22 (1·02-1·46)	1·23 (0·98-1·55)	1·07 (0·81-1·41)
Cardiovascular disorders	1·13 (1·02-1·25)	1·15 (1·02-1·29)	1·02 (0·87-1·19)	1·17 (0·97-1·41)	1·22 (1·00-1·49)	1·01 (0·77-1·33)	1·08 (0·79-1·49)
Neurological or sensory disorders	1·10 (0·99-1·22)	1·14 (1·01-1·28)	1·25 (1·08-1·44)	1·02 (0·85-1·23)	1·03 (0·84-1·27)	1·15 (0·89-1·47)	0·88 (0·63-1·23)
Metabolic disorders	1·09 (0·98-1·21)	1·07 (0·95-1·21)	1·17 (1·01-1·35)	1·19 (1·01-1·41)	1·19 (0·97-1·45)	1·27 (0·99-1·62)	1·08 (0·79-1·47)
Mental disorders	1·18 (1·06-1·32)	1·11 (0·97-1·26)	1·18 (1·01-1·38)	1·09 (0·90-1·32)	1·31 (1·06-1·62)	1·70 (1·33-2·18)	1·21 (0·84-1·72)
Respiratory diseases	1·05 (0·94-1·18)	1·17 (1·03-1·33)	1·16 (0·99-1·36)	0·94 (0·76-1·14)	0·99 (0·79-1·24)	1·07 (0·81-1·42)	1·18 (0·83-1·66)
Dermatological diseases	0·97 (0·85-1·11)	1·06 (0·92-1·22)	1·17 (0·99-1·37)	1·10 (0·90-1·35)	0·89 (0·69-1·15)	0·95 (0·70-1·29)	1·17 (0·81-1·68)
Cancer	1·13 (0·94-1·37)	1·08 (0·86-1·34)	0·81 (0·59-1·12)	0·88 (0·62-1·27)	1·10 (0·75-1·61)	1·05 (0·65-1·71)	1·27 (0·71-2·25)

Table S3. Mutually adjusted prevalence ratios with 95% confidence intervals for new symptom clusters with grade of impairment moderate to strong

	Any	Fatigue	Neurocognitive impairment	Chest symptoms	Smell or taste disorder	Anxiety/depression	Headache/dizziness
Age, per 10 years	1·00 (0·98-1·02)	1·06 (1·02-1·09)	1·05 (1·01-1·09)	0·99 (0·95-1·04)	0·96 (0·92-1·00)	1·03 (0·99-1·08)	0·99 (0·94-1·05)
Sex							
Male (ref.)							
Female	1·37 (1·30-1·44)	1·46 (1·35-1·58)	1·52 (1·37-1·68)	1·33 (1·20-1·48)	1·36 (1·21-1·53)	1·47 (1·30-1·66)	1·49 (1·29-1·72)
University entrance qualification							
Yes (ref.)							
No	1·14 (1·09-1·20)	1·19 (1·10-1·28)	1·09 (0·99-1·20)	1·25 (1·13-1·39)	1·10 (0·99-1·23)	1·15 (1·02-1·29)	1·37 (1·19-1·57)
Smoking status, N (%)							
Never (ref.)							
Former	1·12 (1·06-1·17)	1·12 (1·03-1·21)	1·25 (1·13-1·38)	1·18 (1·06-1·31)	1·07 (0·94-1·21)	1·24 (1·09-1·40)	1·13 (0·97-1·31)
Current	1·22 (1·14-1·31)	1·37 (1·24-1·53)	1·26 (1·09-1·46)	1·27 (1·09-1·48)	1·30 (1·11-1·54)	1·49 (1·26-1·75)	1·34 (1·10-1·64)
BMI, per 5 kg/m ²	1·05 (1·03-1·07)	1·09 (1·05-1·12)	1·06 (1·02-1·11)	1·16 (1·11-1·20)	1·08 (1·02-1·13)	1·04 (0·99-1·10)	1·04 (0·97-1·10)
Time since positive PCR, per month	1·00 (0·98-1·01)	0·98 (0·96-1·01)	1·01 (0·98-1·03)	1·01 (0·98-1·04)	1·03 (1·00-1·07)	1·00 (0·96-1·03)	0·97 (0·94-1·02)
Treatment of acute SARS-CoV-2 infection							
No medical care (ref.)							
Outpatient care	1·69 (1·62-1·77)	2·12 (1·97-2·28)	2·27 (2·05-2·50)	2·43 (2·19-2·69)	1·48 (1·31-1·68)	2·50 (2·23-2·80)	2·79 (2·42-3·21)
Inpatient care	1·82 (1·68-1·97)	2·18 (1·91-2·50)	2·64 (2·24-3·11)	2·52 (2·10-3·02)	1·29 (0·98-1·71)	2·57 (2·06-3·20)	3·16 (2·46-4·05)
Pre-existing conditions							
Musculoskeletal disorders	1·19 (1·14-1·25)	1·23 (1·14-1·33)	1·30 (1·18-1·43)	1·32 (1·19-1·46)	1·24 (1·10-1·40)	1·18 (1·04-1·33)	1·34 (1·17-1·55)
Cardiovascular disorders	1·11 (1·05-1·17)	1·12 (1·03-1·22)	0·99 (0·88-1·11)	1·12 (1·00-1·27)	0·97 (0·83-1·12)	1·02 (0·88-1·18)	0·92 (0·77-1·10)
Respiratory diseases	1·11 (1·05-1·18)	1·20 (1·10-1·31)	1·16 (1·03-1·30)	1·19 (1·05-1·35)	0·93 (0·79-1·09)	1·03 (0·89-1·20)	1·01 (0·84-1·21)
Mental disorders	1·20 (1·14-1·27)	1·26 (1·16-1·37)	1·46 (1·31-1·63)	1·17 (1·03-1·32)	1·07 (0·92-1·24)	1·04 (0·89-1·21)	1·38 (1·17-1·62)
Neurological or sensory disorders	1·09 (1·03-1·15)	1·15 (1·06-1·25)	1·11 (0·99-1·23)	1·25 (1·12-1·40)	1·11 (0·97-1·28)	1·05 (0·91-1·20)	0·97 (0·82-1·15)
Dermatological diseases	1·05 (0·99-1·12)	1·04 (0·94-1·15)	0·97 (0·85-1·11)	1·02 (0·89-1·17)	1·08 (0·92-1·27)	0·93 (0·79-1·11)	0·81 (0·66-1·00)
Cancer	0·99 (0·88-1·10)	0·88 (0·73-1·05)	1·01 (0·82-1·25)	0·97 (0·77-1·24)	1·00 (0·75-1·33)	0·94 (0·71-1·24)	0·87 (0·61-1·24)
Metabolic disorders	1·04 (0·98-1·10)	1·09 (1·00-1·19)	1·15 (1·03-1·28)	1·09 (0·97-1·23)	1·04 (0·90-1·19)	1·07 (0·94-1·23)	1·03 (0·87-1·21)

Table S3. Mutually adjusted prevalence ratios with 95% confidence intervals for new symptom clusters with grade of impairment moderate to strong (...continued)

	Musculoskeletal pain	Upper respiratory symptoms	Rash/paresthesia	Hair loss	Abdominal symptoms	Nausea/vomiting	Chills/fever
Age, per 10 years	1·30 (1·23-1·38)	1·13 (1·04-1·22)	1·12 (1·04-1·22)	0·98 (0·89-1·07)	1·05 (0·93-1·18)	0·99 (0·85-1·16)	1·07 (0·88-1·31)
Sex							
Male (ref.)							
Female	1·55 (1·34-1·78)	1·20 (1·00-1·45)	1·70 (1·38-2·10)	8·32 (5·61-12·3)	1·54 (1·14-2·08)	2·46 (1·55-3·89)	1·67 (0·97-2·85)
University entrance qualification							
Yes (ref.)							
No	1·21 (1·06-1·39)	1·26 (1·04-1·52)	1·04 (0·85-1·26)	1·33 (1·06-1·68)	1·15 (0·87-1·52)	1·13 (0·77-1·66)	1·14 (0·69-1·91)
Smoking status, N (%)							
Never (ref.)							
Former	1·13 (0·98-1·30)	1·07 (0·88-1·30)	1·27 (1·03-1·57)	0·98 (0·76-1·26)	1·07 (0·79-1·46)	1·52 (1·02-2·27)	1·25 (0·75-2·10)
Current	1·44 (1·18-1·75)	1·57 (1·21-2·04)	1·69 (1·28-2·24)	1·24 (0·89-1·74)	1·53 (1·03-2·27)	2·14 (1·32-3·48)	1·95 (1·02-3·73)
BMI, per 5 kg/m ²	1·11 (1·05-1·17)	1·11 (1·02-1·20)	1·08 (0·99-1·17)	1·04 (0·95-1·13)	0·95 (0·81-1·11)	0·80 (0·64-1·00)	0·90 (0·70-1·17)
Time since positive PCR, per month	1·00 (0·96-1·04)	0·95 (0·90-1·01)	0·96 (0·91-1·02)	0·87 (0·81-0·92)	1·01 (0·93-1·09)	0·92 (0·83-1·02)	1·03 (0·89-1·19)
Treatment of acute SARS-CoV-2 infection							
No medical care (ref.)							
Outpatient care	2·61 (2·27-2·99)	2·70 (2·23-3·27)	2·55 (2·07-3·14)	2·44 (1·93-3·09)	2·98 (2·22-3·99)	2·65 (1·79-3·92)	3·64 (2·21-5·98)
Inpatient care	2·58 (2·03-3·30)	2·55 (1·81-3·58)	4·59 (3·38-6·23)	5·60 (4·01-7·82)	3·90 (2·34-6·50)	2·21 (0·95-5·18)	5·85 (2·75-12·4)
Pre-existing conditions							
Musculoskeletal disorders	1·21 (1·06-1·39)	1·33 (1·10-1·61)	1·10 (0·89-1·35)	1·08 (0·84-1·37)	1·14 (0·86-1·53)	1·40 (0·95-2·05)	1·28 (0·80-2·07)
Cardiovascular disorders	1·18 (1·01-1·37)	1·14 (0·92-1·42)	1·32 (1·04-1·67)	1·32 (1·00-1·75)	1·24 (0·88-1·74)	1·41 (0·86-2·32)	1·13 (0·66-1·93)
Respiratory diseases	1·06 (0·90-1·26)	1·60 (1·29-1·98)	1·50 (1·20-1·88)	1·02 (0·75-1·37)	0·97 (0·66-1·42)	1·05 (0·65-1·70)	0·98 (0·52-1·86)
Mental disorders	1·29 (1·10-1·51)	1·14 (0·91-1·43)	0·94 (0·73-1·21)	1·02 (0·77-1·36)	1·60 (1·14-2·24)	1·89 (1·24-2·89)	1·07 (0·57-2·00)
Neurological or sensory disorders	1·12 (0·96-1·30)	1·11 (0·90-1·37)	1·21 (0·97-1·53)	0·98 (0·75-1·30)	0·93 (0·66-1·31)	1·30 (0·85-1·99)	0·77 (0·42-1·42)
Dermatological diseases	0·91 (0·75-1·11)	0·93 (0·72-1·22)	1·07 (0·81-1·41)	1·20 (0·88-1·62)	0·59 (0·36-0·97)	0·44 (0·21-0·92)	0·69 (0·32-1·48)
Cancer	0·99 (0·74-1·34)	1·24 (0·85-1·82)	0·82 (0·50-1·33)	0·82 (0·47-1·43)	1·50 (0·85-2·64)	1·47 (0·69-3·12)	1·49 (0·60-3·69)
Metabolic disorders	1·03 (0·88-1·20)	0·98 (0·79-1·22)	1·10 (0·87-1·38)	1·32 (1·03-1·70)	1·16 (0·82-1·63)	0·99 (0·62-1·59)	1·25 (0·73-2·14)

	18-<30 years	30-<40 years	40-<50 years	50-<60 years	60-65 years		18-<30 years	30-<40 years	40-<50 years	50-<60 years	60-65 years
Average total loss - men	6.7	7.9	10.7	11.8	13.6	Average total loss - women	5.5	6.5	9.2	11.6	14.9
Unattributed - men	1.27	1.55	2.06	2.69	3.10	Unattributed - women	1.02	0.61	1.25	2.47	4.13
Unattributed - women	1.69	1.43	1.54	2.68	2.53	Unattributed - men	0.91	0.68	0.51	2.05	2.57
Fatigue - men	1.51	1.78	2.84	2.65	2.99	Fatigue - women	1.09	1.92	3.19	2.98	3.23
Fatigue - women	1.58	2.58	2.80	1.93	2.19	Fatigue - men	1.52	2.55	2.70	1.92	2.41
Neurocognitive impairment - men	0.79	0.60	1.54	1.36	1.58	Neurocognitive impairment - women	1.16	0.88	1.51	1.56	1.73
Neurocognitive impairment - women	0.83	0.90	1.91	1.91	2.98	Neurocognitive impairment - men	1.42	1.67	2.78	2.39	2.69
Chest symptoms - men	0.88	0.83	0.91	1.73	2.71	Chest symptoms - women	0.37	0.62	0.21	1.20	2.12
Chest symptoms - women	1.80	1.44	1.79	2.23	2.00	Smell or taste disorder - men	0.52	0.68	1.17	1.37	1.75
Smell or taste disorder - men	1.01	1.06	0.92	0.52	0.63	Smell or taste disorder - women	0.23	0.38	0.29	0.15	0.42
Smell or taste disorder - women	1.18	1.26	1.23	1.29	0.55	Anxiety/Depression - men	0.04	0.39	0.47	0.97	0.24
Anxiety/Depression - men	0.01	0.54	0.51	0.79	0.77	Anxiety/Depression - women	0.16	0.45	0.83	0.83	0.45
Anxiety/Depression - women	0.68	0.25	1.05	0.78	0.94	Headache/dizziness - men	1.36	0.53	1.06	0.63	1.33
Headache/dizziness - men	0.51	0.46	0.59	0.66	0.41	Headache/dizziness - women	0.73	0.97	0.53	0.46	0.61
Headache/dizziness - women	0.53	0.54	0.51	0.66	0.91	Musculoskeletal pain - men	0.41	0.59	0.61	0.83	0.82
Musculoskeletal pain - men	0.05	0.21	-0.11	0.53	0.40	Musculoskeletal pain - women	0.07	0.06	-0.02	0.90	0.79
Musculoskeletal pain - women	0.37	0.67	0.80	0.80	0.53	Upper respiratory symptoms - men	0.37	0.45	1.14	0.72	0.47
Upper respiratory symptoms - men	0.19	0.29	0.26	0.33	-0.02	Upper respiratory symptoms - women	0.14	-0.15	0.29	0.21	-0.21
Upper respiratory symptoms - women	0.07	0.14	0.14	0.74	0.57	Rash/paresthesia - men	0.15	0.17	0.14	1.00	0.38
Rash/paresthesia - men	0.13	0.24	0.47	0.04	0.32	Rash/paresthesia - women	0.09	0.33	0.43	0.11	0.89
Rash/paresthesia - women	0.07	0.31	0.63	0.22	0.47	Hair loss - men	0.14	0.38	1.02	0.32	0.64
Hair loss - men	0.01	-0.02	-0.01	-0.00	0.17	Hair loss - women	0.02	-0.05	-0.03	-0.00	0.07
Hair loss - women	-0.03	0.48	0.08	0.13	0.37	Abdominal symptoms - men	-0.01	0.03	0.13	0.14	-0.28
Abdominal symptoms - men	-0.04	0.11	0.15	0.20	-0.04	Abdominal symptoms - women	0.21	0.07	0.12	0.30	0.01
Abdominal symptoms - women	0.02	0.09	0.04	0.09	-0.09	Nausea/vomiting - men	0.24	0.09	0.06	0.25	0.45
Nausea/vomiting - men	0.22	0.03	0.08	0.06	0.34	Nausea/vomiting - women	0.21	0.13	0.17	0.28	0.15
Nausea/vomiting - women	0.21	0.07	0.32	0.24	0.09	Chills/fever - men	0.05	0.14	0.14	-0.10	0.07
Chills/fever - men	-0.01	0.10	0.15	-0.10	-0.09	Chills/fever - women	0.14	0.04	0.23	0.40	0.35
Chills/fever - women	0.17	0.14	0.17	0.21	0.24						

Figure S6. Attributable percentage loss of general health (left panel) and working capacity (right panel), stratified by age categories and sex.




Figure S7. Pairwise Pearson's correlation coefficient between measures of recovered general health, working capacity, physical and mental health score (SF-12), and fatigue assessment.

Table S8. Participation according to age and sex.

Sex	Source population*	Participants (%)
Male	24 959	4829 (19·3)
Female	25 483	6881 (27·0)
Total	50 442	11 710 (23·2)

Age class (years)	Source population	Participants (%)
<30	14 045	2474 (17·6)
30 - <40	10 710	2158 (20·1)
40 - <50	9504	2075 (21·8)
50 - <60	11 633	3443 (29·6)
≥ 60	4565	1560 (34·2)
Total	50 457	11 710 (23·2)

* n=15 unknown or non-binary sex